Overview

Founded in late 2000 by scientists from the Massachusetts Institute of Technology, EngeneOS is using the information from the genomics revolution combined with the tools of engineering to carry out technology and product development to design and build programmable biomolecular devices consisting of hybrid natural/nonnatural materials addressing a range of commercial applications.

EngeneOS’ technology platform starts with the “source code” of nature's operating system, embodied in the genomic sequences of various organisms. The company is combining this information with modern molecular biology techniques, engineering and design principles to develop engineered genomic operating systems. These systems will consist of component device modules supported by modeling and design tools.

EngeneOS will develop tools for small-molecule drug discovery, functional genomics, biotherapeutics discovery and manufacturing, molecular diagnostics, drug delivery and enzyme optimization and biocatalysis.

Partners

EngeneOS said its platform will be available for licensing and that it will collaborate with partners in both technology and product development.